• LAST PRICE
    2.2700
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    1.9800/ 1
  • Ask / Lots
    2.7500/ 4
  • Open / Previous Close
    0.0000 / 2.2700
  • Day Range
    ---
  • 52 Week Range
    Low 1.9200
    High 10.3541
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
Table Data Not Available
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesSRZN
Surrozen Inc
79.7M
-1.6x
---
United StatesHCWB
HCW Biologics Inc
86.0M
-6.7x
---
United StatesSPPI
Spectrum Pharmaceuticals Inc
86.6M
-0.6x
---
United StatesLIFE
aTyr Pharma Inc
81.0M
-1.8x
---
United StatesTSHA
Taysha Gene Therapies Inc
72.3M
-0.4x
---
United StatesEPIX
ESSA Pharma Inc
77.6M
-2.1x
---
As of 2022-09-27

Company Information

Surrozen Inc. is a preclinical stage biopharmaceutical company. The Company is engaged in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The Company's product candidates are multi-specific, antibody-based therapeutics that mimic the roles of naturally occurring Wnt or R-spondin proteins, which are involved in the activation and enhancement of the Wnt pathway. Its two technologies, Surrozen Wnt signal Activating Protein (SWAP) and Surrozen Wnt signal Enhancer Engineered for Tissue Specificity (SWEETS), enable to selectively modulate Wnt signaling through the generation of Wnt and R-spondin mimetics. SWAP molecules are designed to mimic the activity of naturally occurring Wnt proteins. SWEETS molecules are designed to amplify the body’s response to naturally occurring Wnt proteins. The Company's two lead product candidates include SZN-1326 and SZN-043.

Contact Information

Headquarters
171 Oyster Point Blvd, Suite 400SOUTH SAN FRANCISCO, CA, United States 94080
Phone
650-475-2820
Fax
302-655-5049

Executives

Independent Chairman of the Board,
Tim Kutzkey
President, Chief Executive Officer, Director
Craig Parker
Chief Financial Officer
Charles Williams
Chief Scientific Officer
Wen-Chen Yeh
Chief Medical Officer
Geertrui Vanhove

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$79.7M
Revenue (TTM)
$0.00
Shares Outstanding
35.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-1.45
Book Value
$3.13
P/E Ratio
-1.6x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.